Abbott Gains Pain-Relief Drug In $190M Deal
Looking to expand its pain treatment portfolio and boost its expertise in biologics, Abbott Laboratories has snapped up PanGenetics BV's experimental drug for chronic pain in a deal worth up to...To view the full article, register now.
Already a subscriber? Click here to view full article